The endothelium plays an important role in maintaining vascular homeostasis by synthesizing and releasing several mediators of vasodilation, which include prostacyclin (PGI2), nitric oxide, and endothelium-derived hyperpolarizing factor (EDHF). We have recently defined the role of nitric oxide and PGI2 in the dilation of submucosal intestinal arterioles from patients with normal bowel function. However, significant endothelium-dependent dilator capacity to ACh remained after inhibiting both these mediators. The current study was designed to examine the potential role of EDHF in human intestinal submucosal arterioles. ACh elicited endothelium-dependent relaxation in the presence of inhibitors of nitric oxide synthase and cyclooxygenase (23 ± 10%, n = 6). This ACh-induced relaxation was inhibited and converted to constriction by catalase (−53 ± 10%, n = 6) or KCl (−30 ± 3%, n = 7), whereas 17-octadecynoic acid and 6-(2-propargylloxyphenyl) hexanoic acid, two inhibitors of cytochrome P450 monooxygenase, had no significant effect (3 ± 1% and 20 ± 8%, n = 5, respectively). Exogenous H2O2 elicited dose-dependent relaxation of intact microvessels (52 ± 10%, n = 7) but caused frank vasoconstriction in arterioles denuded of endothelium (−73 ± 8%, n = 7). ACh markedly increased the dichlorofluorescein fluorescence in intact arterioles in the presence of nitric oxide synthase and cyclooxygenase inhibitors compared with control and compared with catalase-treated microvessels (363.6 ± 49, 218.8 ± 10.6, 221.9 ± 27.9, respectively, P < 0.05 ANOVA, n = 5 arbitrary units). No changes in the dichlorofluorescein fluorescence were recorded in vessels treated with ACh alone. These results indicate that endothelial production of H2O2 occurs in response to ACh in human gut mucosal arterioles but that H2O2 is not an EDHF in this tissue. Rather, we speculate that it stimulates the release of a chemically distinct EDHF.
Localization of nitric oxide synthase in saphenous vein grafts harvested with a novel “no-touch” technique: Potential role of nitric oxide contribution to improved early graft patency rates
